FFA
AVIR icon

Frazier Financial Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Frazier Financial Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-120
Closed -$398 – 872
2024
Q2 		$398 Hold
120
– – ﹤0.01% 907
2024
Q1 		$485 Hold
120
– – ﹤0.01% 842
2023
Q4 		$366 Buy
+120
New +$363 ﹤0.01% 814

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Frazier Financial Advisors's AVIR Position: Q3 2024 in Review

Frazier Financial Advisors sold out of Atea Pharmaceuticals (AVIR) in Q3 2024, closing a stake of 120 shares — an estimated $398 sold.

Frazier Financial Advisors first reported a position in AVIR in Q4 2023 and held it in 3 quarters. The position peaked at $485 in Q1 2024. 108 funds tracked by Wall St. Rank hold AVIR as of Q3 2024.

  • Frazier Financial Advisors reported no remaining Atea Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Frazier Financial Advisors sold 120 Atea Pharmaceuticals shares in Q3 2024, an estimated $398.
  • Frazier Financial Advisors first reported a position in Atea Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Frazier Financial Advisors's Atea Pharmaceuticals position peaked at $485 in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2024.

Based on Frazier Financial Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.